Intraocular pressure and tolerability Study of Preserved Bimatoprost 0.1% (BMD) or Tafluprost Unit Dose Preservative Free 15microgram/ml (TUDPF) (Saflutan), in patients with Ocular hypertension or glaucoma suitable for prostaglandin therapy: A Randomized, single masked, 3 month cross-over, Investigator led, European multicentre Trial, II (SPORT II)

Trial Profile

Intraocular pressure and tolerability Study of Preserved Bimatoprost 0.1% (BMD) or Tafluprost Unit Dose Preservative Free 15microgram/ml (TUDPF) (Saflutan), in patients with Ocular hypertension or glaucoma suitable for prostaglandin therapy: A Randomized, single masked, 3 month cross-over, Investigator led, European multicentre Trial, II (SPORT II)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 May 2016

At a glance

  • Drugs Bimatoprost (Primary) ; Tafluprost
  • Indications Glaucoma; Ocular hypertension
  • Focus Therapeutic Use
  • Acronyms SPORT II
  • Most Recent Events

    • 11 May 2016 Dose of the Bimatoprost changed from 0.1% to 0.01%.
    • 24 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top